Categories
News

Nimble Therapeutics spins out of Roche, saving Madison jobs

A new drug discovery and development company is taking root in Madison, and it will prevent more than a dozen skilled scientists here from losing their jobs.

Nimble Therapeutics formed in April, spun out of Roche Sequencing Solutions, originally NimbleGen Systems, which is slated to close by June 2020.

Read more

Categories
News

Roche Spinout Nimble Therapeutics Bags $10M to Find New Peptide Drugs

For the past five years, Jigar Patel and a group of fellow Roche employees have been quietly developing drug discovery technology at the global pharma company’s outpost in Madison, WI. Now, they’re setting out on their own to see if their approach to identifying promising peptide-based therapies can have an impact on the sector.

Read more

Categories
News Press Release

Nimble Therapeutics Spins Out from Roche to Commercialize Novel Drug Discovery Technology with Financing from Telegraph Hill Partners

April 30, 2019 (Madison, WI): Nimble Therapeutics has begun operating as a standalone business after spinning out from F. Hoffmann La Roche (SIX: RO, ROG; OTCQX: RHHBY) to commercialize its proprietary chemical synthesis technology for drug discovery and development. The company also completed a Series A financing led by Telegraph Hill Partners (San Francisco, CA).

Initially, Nimble Therapeutics will leverage the unparalleled speed and flexibility of its proprietary chemical synthesis platform, developed at Roche, to accelerate the discovery and optimization of macrocyclic peptidomimetics as novel therapeutics. “As a fully independent company, Nimble Therapeutics will establish strategic partnerships with pharmaceutical companies to jointly develop unique drug candidates more efficiently across many therapeutic areas”, notes Dr. Jigar Patel, who led the development of the technology and will serve as CEO of the company.

Nimble Therapeutics has hired the former Roche team that helped develop its chemical synthesis technology for drug discovery. The company’s platform, validated over many years and with over 20+ collaborations, provides the ability to synthesize millions of unique natural and modified peptide-based molecules simultaneously. These molecules can be efficiently screened and optimized through rapid iterations to identify novel entities with the desired characteristics using the Nimble platform.

As part of its growth strategy, the company will expand its current collaborations and strategically develop new relationships in key therapeutic areas. “The Roche team saw the value in separating the business to enable it to expand its platform and work on a variety of therapeutic areas with strategic partners”, said Dr. Deval Lashkari, Senior Partner at Telegraph Hill Partners and board director at Nimble Therapeutics, “Nimble’s capabilities are truly revolutionary and we are excited to work with the company in a shared vision to grow the business into a leading drug discovery partner for the pharmaceutical industry.”